Xenetix + Visipaque
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging
Trial Timeline
May 1, 2006 → Jun 1, 2009
NCT ID
NCT00347022About Xenetix + Visipaque
Xenetix + Visipaque is a approved stage product being developed by Guerbet for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT00347022. Target conditions include Diagnostic Imaging.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00347022 | Approved | Completed |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| BAY86-4367 + BAY86-4367 | Bayer | Phase 1 | 30 |
| F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Pre-clinical | 20 |
| Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) | Bayer | Phase 3 | 74 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |